|
|
Post by mindovermatter on Mar 11, 2016 10:20:08 GMT -5
We will find out soon enough. I've been on record that I think one will happen but looking at all the bad luck and miss steps Mannkind has had, I won't be shocked if SNY walks away scot-free
|
|
|
|
Post by mindovermatter on Mar 10, 2016 21:59:53 GMT -5
A cover all bases patent for technosphere. (?)
disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery
The F in FDKP can be replaced. (?) xDKP ?
This is what this patent could be about. These particles can be administered by various routes of administration. As dry powders these particles can be delivered by inhalation to specific areas of the respiratory system, depending on particle size. Additionally, the particles can be made small enough for incorporation into an intravenous suspension dosage form. Oral delivery is also possible with the particles incorporated into a suspension, tablets or capsules; or dissolved in an appropriate solvent. Diketopiperazines may also facilitate absorption of an associated drug. Nonetheless difficulties can arise when diketopiperazines are diacids, or are in diacid form(s), due to the limited solubility of these diacids at non-basic pH (i.e., neutral or acid pH). Another difficulty arises because these diacid diketopiperazines may form disadvantageous association(s) with some drugs.
patents.justia.com/patent/9259471come on Peppy, the F was replaced because Mannkind realized it could be mistaken for "F"udster. |
|
|
|
Post by mindovermatter on Mar 10, 2016 17:14:37 GMT -5
The Legal Counsel Reqs was removed today 3/10/16. You know that is definite proof the company was sold.  |
|
|
|
Post by mindovermatter on Mar 10, 2016 12:24:19 GMT -5
filed in 11/18/15, Kelly Kraft www.freepatentsonline.com/y2016/0067183.htmlDisclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery .... Example 1 Synthesis of Substituted DKP Analogs Example 2 Pharmacokinetics of GLP-1/DKP Analogues Administered Via Pulmonary Insufflation in Rats Example 3 Glucose Reduction in Rats Administered xDKP/Insulin (TI) Powders Example 4 Insulin Analysis in Rats Administered Substituted DKP/Insulin Example 5 Glucose and Insulin Analysis in Rats Administered Substituted DKP Powders Just another patent or is there something special about this one in particular? It appears it is an update to an existing patent. Unless I am misinformed, this is typical. It appears that the company continues to refine a patented process and when they do, they apply for a patent to protect that new process. This appears to be one of those instances. CROSS-REFERENCE TO RELATED APPLICATIONS This application is a divisional of U.S. patent application Ser. No. 14/536,168, filed Nov. 7, 2014, which is a continuation of U.S. patent application Ser. No. 13/649,430, filed Oct. 11, 2012, now U.S. Pat. No. 8,906,926, which is a continuation of U.S. patent application Ser. No. 12/649,210, filed Dec. 29, 2009, now U.S. Pat. No. 8,314,106, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61/141,207 filed Dec. 29, 2008; the entire contents of each of these applications is incorporated by reference herein. |
|
|
|
Post by mindovermatter on Mar 9, 2016 14:36:30 GMT -5
Considering that Sanofi was in charge of marketing AND sales, it would be very easy for Mannkind to drag SNY into this suit should it move forward. I don't think it is something Sanofi would want but would be a good move on Mannkind's part. It also could be a very good point to have the suit dropped if Mannkind's lawyers explain to the judge that the merits of the lawsuit have no grounds as Mannkind was using info their sales and marketing partner was giving them. Why sue us and not also Sanofi? |
|
|
|
Post by mindovermatter on Mar 9, 2016 7:49:19 GMT -5
If stock prices were based on journal publications and patents MNKD would be worth $50 a share!
I believe there is a very good reason why Andrea Leone Bay left Mannkind for Receptor Life Sciences and that is because, unlike Mannkind, it has the resources to see her work come to life instead of just get moth balled. I have no idea if RLS will be successful but look at every partner Mannkind has worked with. Not ONE has been successful.
|
|
|
|
Post by mindovermatter on Mar 8, 2016 20:40:50 GMT -5
Ho much are those dozen or so class action law suits expected to slow MNKD's recovery? Ballsy of you to assume there is going to be a recovery. You are expecting a company that has never sold or marketed a drug to be successful when a major BP, regardless of their intentions, wasn't successful to be successful. That's a tall order. It is why I hope the company is actively shopping for a buyer. |
|
|
|
Post by mindovermatter on Mar 8, 2016 16:55:39 GMT -5
I'll just be the first to suggest, just to get it out of the way, that this job position is to help with pending sale of the company coming soon for $26 pps. |
|
|
|
Post by mindovermatter on Mar 8, 2016 16:30:27 GMT -5
inittowinit I hope this board is keeping you suffiently amused during your recovery! I'm not selling. Still think we are going to hit $27 by year end, probably due to a sale of Afrezza and/or worldwide partnerships. Wowwwwwwwww. And I was hoping for $4! $27 is wishful thinking. $26 is more on target. |
|
|
|
Post by mindovermatter on Mar 8, 2016 16:10:01 GMT -5
inittowinit I hope this board is keeping you suffiently amused during your recovery! I'm not selling. Still think we are going to hit $27 by year end, probably due to a sale of Afrezza and/or worldwide partnerships. $27 pps gives a ~11.5 BILLION market cap to Mannkind. What makes you believe that it will get that high? |
|
|
|
Post by mindovermatter on Mar 8, 2016 11:52:50 GMT -5
Not sure if this has been pointed out here (think it was on yazoo):
VALENCIA, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will release its 2015 fourth quarter and full year financial results on Monday, March 14, 2016 and its management will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM (Eastern Time) on March 14, 2016. - See more at: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=959245#sthash.dgGz3JS3.dpuf
Wonder what these "other Company developments" might be?
OOG This was Q3-15 release statement: VALENCIA, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2015 third quarter financial results on Monday, November 9, 2015 and its management will host a conference call to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 9, 2015. - See more at: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=939786#sthash.5eWaCpa5.dpuf. I'm more interested to see besides Matt who will be speaking. If Matt was smart, he'd bring in Jim Harbaugh to speak. That should be worth at least a dollar bump in the pps. |
|
|
|
Post by mindovermatter on Mar 8, 2016 11:34:00 GMT -5
Not sure if this has been pointed out here (think it was on yazoo):
VALENCIA, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will release its 2015 fourth quarter and full year financial results on Monday, March 14, 2016 and its management will host a conference call to discuss the fourth quarter and full year financial results and other Company developments at 5:00 PM (Eastern Time) on March 14, 2016. - See more at: investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=959245#sthash.dgGz3JS3.dpuf
Wonder what these "other Company developments" might be?
OOG The highlighted part is standard wording in all of their releases. Go back to all of their quarterly announcements and you'll see it printed there too. There is literally nothing to read into unless the company actually releases something. |
|
|
|
Post by mindovermatter on Mar 7, 2016 22:36:48 GMT -5
News actually broke Sunday at 10 pm PST due to it being released in Europe on Monday morning. I vividly remember because I woke my wife up and she hit me for doing so. Let's hope there is fantastic news next Monday thought I am not going to lose any sleep over thinking that there will be. If she hit you for good news, I'd hate to think of how bruised you are now. Though, perhaps she wasn't just cranky about being awakened. Did she mutter something about "G.d d.mn sandbagging frogs... what a mistake" before rolling over and going back to sleep. Glad I don't have a spouse. I'd probably have some broken bones or lacerations based on the amount of savings lost on MNKD. After all that has transpired, I'm actually sleeping in the used kitty litter. |
|
|
|
Post by mindovermatter on Mar 7, 2016 21:15:38 GMT -5
Looking back Anybody remember August 11 (Monday) pre-market announcement? Monday August 11, 2014 we all awoke to the announcement of the Sanofi partnership. On that day there was already a pre-scheduled earnings call for that day. It makes one wonder if something or some news is ahead. I remember being very excited that day. Nobody knows if there is more attached to the earnings call next Monday but it makes me wonder or speculate there might be more news coming pre-market Monday March 14th 2016 like there was August 11, 2014. Below is an excerpt from the press release that was later issued. PARIS and VALENCIA, Calif., Aug. 11, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015. Less News actually broke Sunday at 10 pm PST due to it being released in Europe on Monday morning. I vividly remember because I woke my wife up and she hit me for doing so. Let's hope there is fantastic news next Monday thought I am not going to lose any sleep over thinking that there will be. |
|
|
|
Post by mindovermatter on Mar 7, 2016 19:11:25 GMT -5
What are the odds that it will be informative? |
|
